



SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")

Total Voting Rights

Following the admission today of 129,736 new ordinary shares of 1 pence each to satisfy the exercise of share options, the Company has 258,909,199 Ordinary Shares in issue. This figure of 258,909,199 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

For more information please contact:

SkinBioTherapeutics plc

+44 (0) 191 495 7325

Stuart J. Ashman, CEO
Emily Bertram, CFO

Singer Capital Markets (Nominated Adviser & Broker)

+44 (0) 020 7496 3000

Philip Davies
James Todd
Patrick Weaver

Vigo Consulting (financial press)

+44 (0) 20 7390 0230

Rozi Morris, Melanie Toyne-Sewell

SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix[®], is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix[®]) and food supplements that harness the gut-skin axis (AxisBiotix[™]). The cosmetic pillar has a partnership with Croda plc where SkinBiotix[®] is being used as an active skin ingredient with the Croda trade name, Zenakine[™]. The AxisBiotix[™] pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:

www.skinbiotherapeutics.com.

information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRPPUBCGUPQGAG